
Voyager Therapeutics (VYGR) Stock Forecast & Price Target
Voyager Therapeutics (VYGR) Analyst Ratings
Bulls say
Voyager Therapeutics Inc. is positioned for significant growth due to its innovative TRACER gene therapy platform, which has the potential to enable durable efficacy with a single administration while targeting severe neurological diseases. The company's robust pipeline includes several programs with promising clinical validation prospects, alongside co-commercialization options that could enhance long-term revenue potential. Furthermore, the absence of serious adverse events related to its therapies and an extended cash runway into mid-2027 allows Voyager to focus on its Alzheimer’s programs, reinforcing a favorable outlook for shareholder value creation.
Bears say
Voyager Therapeutics Inc. faces significant financial risks due to its lack of sales revenue and a protracted path to profitability, with a reported net loss of ($1.13) per share and potential delays in clinical studies that could further impact revenue projections. The company's pipeline, which includes programs like VY7523 and VY9323, is at risk due to competition from other tau antibody therapies currently in clinical development, coupled with the uncertainties surrounding their efficacy and the possibility of regulatory approval delays extending to 2033 and 2034. Additionally, any failure in meeting production needs for clinical studies or securing favorable agency decisions could substantially jeopardize Voyager's financial outlook and valuation estimates.
This aggregate rating is based on analysts' research of Voyager Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Voyager Therapeutics (VYGR) Analyst Forecast & Price Prediction
Start investing in Voyager Therapeutics (VYGR)
Order type
Buy in
Order amount
Est. shares
0 shares